Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные подходы к лечению хронической сердечной недостаточности у больных хронической обструктивной болезнью легких
Современные подходы к лечению хронической сердечной недостаточности у больных хронической обструктивной болезнью легких
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269–80.
2. Jessup M, Brozena S. Medical progress: heart failure. N Engl J Med 2003; 348: 2007–18.
3. Egred M, Shaw S, Mohammad P et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98: 493–97.
4. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Сердечная недостаточность. 2013; 81: 1–94.
5. Кароли Н.А., Ребров А.П. Хроническая обструктивная болезнь легких и кардиоваскулярная патология. Клиницист. 2007; 1: 13–9.
6. Белевский А.С. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. М.: Российское респираторное общество, 2012.
7. Rutten FH. Diagnosis and management of heart failure in COPD. Eur Respir Monogr 2013; 59: 50–63.
8. Бова А.А., Лапицкий Д.В. Современные подходы к диагностике и лечению ишемической болезни сердца у больных хронической обструктивной болезнью легких. Медицинские новости. 2007; 9: 7–14.
9. Mortensen EM, Copeland LA, Pugh MJV et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
10. Mancini GB, Etminan M, Zhang B et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47 (12): 2554–60.
11. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci 2012; 123 (8): 487–98.
12. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117 (3): 234–42.
13. Cazzola M, Noschese P, D’Amato G et al. The Pharmacological Treatment of Uncomplicated Arterial Hypertension in Patients with Airway Dysfunction. Chest 2002: 121 (1): 230–41.
14. Andreas S, Herrmann-Lingen C, Raupach T et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006; 27 (5): 972–79.
15. Ling Y, Saleem W, Shee CD. Concomitant use of beta-blockers and beta2-agonists. Eur Respir J 2008; 31 (4): 905–6.
16. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49 (2): 171–80.
17. Egred M, Shaw S, Mohammad B et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98 (7): 493–7.
18. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339 (8): 489–97.
19. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulm Dis 2007; 2: 535–40.
20. Hawkins NM, Huang Z, Pieper KS et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Failure 2009; 11: 292–8.
21. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 4: CD003566.
22. Van Gestel YR, Hoeks SE, Sin DD et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178 (7): 695–700.
23. Hawkins NM, Petrie MC, Macdonald MR et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol 2011; 57: 2127–38.
24. Etminan et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine 2012; 12: 48.
25. Ekström MP, Hermansson A, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187 (7): 715–20.
26. Dorow P, Thalhofer S, Bethge H et al. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): S36–S44.
27. Dorow P, Bethge H, Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
28. Hawkins NM, MacDonald MR, Petrie MC et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009; 11: 684–90.
29. Jabbour A, Macdonald PS, Keogh AM et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780–7.
30. Dransfield MT, Rowe SM, Johnson JE et al. Beta-blocker use and the risk of death in hospitalized patients with acute exacerbations of COPD. Thorax 2008; 63: 301–5.
31. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44 (3): 497–502.
32. Kotlyar E, Keogh AM, Macdonald PS et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21 (12): 1290–5.
33. Andrikopoulos G, Pastromas S, Kartalis A et al. Inadequate Heart Rate Control Is Associated with Worse Quality of Life in Patients with Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. The RYTHMOS Study. Hellenic J Cardiol 2012; 53: 118–26.
34. Архипов В.В. Хроническая обструктивная болезнь легких и хроническая сердечная недостаточность: особенность совместной терапии. Пульмонология. 2010; 6: 120–6.
2. Jessup M, Brozena S. Medical progress: heart failure. N Engl J Med 2003; 348: 2007–18.
3. Egred M, Shaw S, Mohammad P et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98: 493–97.
4. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Сердечная недостаточность. 2013; 81: 1–94.
5. Кароли Н.А., Ребров А.П. Хроническая обструктивная болезнь легких и кардиоваскулярная патология. Клиницист. 2007; 1: 13–9.
6. Белевский А.С. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. М.: Российское респираторное общество, 2012.
7. Rutten FH. Diagnosis and management of heart failure in COPD. Eur Respir Monogr 2013; 59: 50–63.
8. Бова А.А., Лапицкий Д.В. Современные подходы к диагностике и лечению ишемической болезни сердца у больных хронической обструктивной болезнью легких. Медицинские новости. 2007; 9: 7–14.
9. Mortensen EM, Copeland LA, Pugh MJV et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
10. Mancini GB, Etminan M, Zhang B et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47 (12): 2554–60.
11. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci 2012; 123 (8): 487–98.
12. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117 (3): 234–42.
13. Cazzola M, Noschese P, D’Amato G et al. The Pharmacological Treatment of Uncomplicated Arterial Hypertension in Patients with Airway Dysfunction. Chest 2002: 121 (1): 230–41.
14. Andreas S, Herrmann-Lingen C, Raupach T et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006; 27 (5): 972–79.
15. Ling Y, Saleem W, Shee CD. Concomitant use of beta-blockers and beta2-agonists. Eur Respir J 2008; 31 (4): 905–6.
16. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49 (2): 171–80.
17. Egred M, Shaw S, Mohammad B et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98 (7): 493–7.
18. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339 (8): 489–97.
19. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulm Dis 2007; 2: 535–40.
20. Hawkins NM, Huang Z, Pieper KS et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Failure 2009; 11: 292–8.
21. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 4: CD003566.
22. Van Gestel YR, Hoeks SE, Sin DD et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178 (7): 695–700.
23. Hawkins NM, Petrie MC, Macdonald MR et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol 2011; 57: 2127–38.
24. Etminan et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine 2012; 12: 48.
25. Ekström MP, Hermansson A, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187 (7): 715–20.
26. Dorow P, Thalhofer S, Bethge H et al. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): S36–S44.
27. Dorow P, Bethge H, Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
28. Hawkins NM, MacDonald MR, Petrie MC et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009; 11: 684–90.
29. Jabbour A, Macdonald PS, Keogh AM et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780–7.
30. Dransfield MT, Rowe SM, Johnson JE et al. Beta-blocker use and the risk of death in hospitalized patients with acute exacerbations of COPD. Thorax 2008; 63: 301–5.
31. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44 (3): 497–502.
32. Kotlyar E, Keogh AM, Macdonald PS et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21 (12): 1290–5.
33. Andrikopoulos G, Pastromas S, Kartalis A et al. Inadequate Heart Rate Control Is Associated with Worse Quality of Life in Patients with Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. The RYTHMOS Study. Hellenic J Cardiol 2012; 53: 118–26.
34. Архипов В.В. Хроническая обструктивная болезнь легких и хроническая сердечная недостаточность: особенность совместной терапии. Пульмонология. 2010; 6: 120–6.
Авторы
Н.А.Кароли, А.П.Ребров
ГБОУ ВПО Саратовский государственный медицинский университет им. В.И.Разумовского Минздрава России
ГБОУ ВПО Саратовский государственный медицинский университет им. В.И.Разумовского Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.